Clinical Trial Update: Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4 [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 trial evaluating sofosbuvir plus daclatasvir with or without ribavirin for chronic hepatitis C virus infection genotype 4 completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Ribavirin (ribavirin)
• Sofosbuvir (sofosbuvir)

Snippet

Sponsor: Beni-Suef University | Conditions: Chronic Hepatitis C Virus Infection | Phase 2, Phase 3 | Status: COMPLETED